Aims : The interaction between metabolic dysfunction and respiratory diseases is increasingly recognized and may contribute to poor disease and/or treatment outcome, pathophysiological features. For example, obesity and the presence of metabolic syndrome has a dramatic effect on the severity and drug response of asthmatics. Furthermore, metabolic reprogramming has been found to play a key role in structural cell function in lung and airway fibrosis, in pulmonary vessels in pulmonary hypertension and in regulating the innate immune response to infection. The aim of this session is to describe the metabolic repatterning processes observed in various lung diseases and highlight the potential for therapeutic interventions implicit in these changes with the goal of improving clinical management.